Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8337596 | 0.87 | GAA (0.49) | LIPELMNAKMT2ATBXAS1GAA | |
| SCHEMBL68851 | 0.85 | CYP4Z1 (0.62) | LIPELMNACYP4Z1KMT2ATBXAS1 | |
| SCHEMBL24819498 | 0.83 | LMNA (0.69) | LMNAKMT2AMAPTGAA | |
| SCHEMBL4406559 | 0.82 | CYP4F2 (0.58) | LIPELMNAKMT2AMAPTGAA | |
| SCHEMBL181473 | 0.82 | HPGD (0.61) | LIPECYP4Z1TBXAS1MAPTGAA | |
| SCHEMBL924496 | 0.82 | KMT2A (0.63) | KMT2AGAAMEN1CYP3A4CYP2C19 | |
| SCHEMBL18932531 | 0.82 | CYP4Z1 (0.55) | LIPELMNACYP4Z1KMT2ATBXAS1 | |
| SCHEMBL18891535 | 0.81 | ALDH1A1 (0.70) | LIPEMAPTGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL8080255 | 0.81 | KMT2A (0.54) | LMNAKMT2AMAPTGAAMEN1 | |
| SCHEMBL1136018 | 0.80 | GAA (0.53) | LIPECYP4Z1KMT2ATBXAS1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011109525-A1 | Aging-Related Circulating Particle-Associated Lipoprotein B Oxidase (apoBNOX) and Inhibitors Thereof | NOX TECHNOLOGIES, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-1494658-B1 | NATURAL PHENOLIC PRODUCTS AND DERIVATIVES THEREOF FOR PROTECTION AGAINST NEURODEGENERATIVE DISEASES | PULEVA BIOTECH SA (ES) | 2006-01-04 | — | — | EP | disclosed |
| EP-1494658-A1 | NATURAL PHENOLIC PRODUCTS AND DERIVATIVES THEREOF FOR PROTECTION AGAINST NEURODEGENERATIVE DISEASES | PULEVA BIOTECH, S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| US-20030236202-A1 | Natural products and derivatives thereof for protection against neurodegenerative diseases | PULEVA BIOTECH, S.A. (ES) | 2003-12-25 | — | — | US | disclosed |
| WO-2003082259-A1 | NATURAL PHENOLIC PRODUCTS AND DERIVATIVES THEREOF FOR PROTECTION AGAINST NEURODEGENERATIVE DISEASES | PULEVA BIOTECH, S.A. (ES) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236202-A1 | Natural products and derivatives thereof for protection against neurodegenerative diseases | SNCA, HTT, PARK7 | LIPE 3172/4885LMNA 543/4885CYP4Z1 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.